Cantor Fitzgerald Raises Zevra Therapeutics EPS Forecast

Summary

Cantor Fitzgerald raised Zevra Therapeutics’ (NASDAQ: ZVRA) fiscal year 2025 EPS forecast from a loss of $0.17 to a profit of $1.58. The firm maintains an ‘Overweight’ rating with a target price of $29.00, while the consensus estimate for the company’s current annual EPS is a loss of $1.95. Zevra recently reported quarterly EPS of ($0.06), exceeding expectations. Institutional investors own 35.03% of the stock, which has a market cap of $685.14 million, and the current share price is $12.53.Market Beat+ 2

Impact Analysis

This is a company-level event concerning Zevra Therapeutics. The significant upward revision in the EPS forecast by Cantor Fitzgerald suggests improved financial performance expectations, potentially due to favorable business developments or cost management within the company. The stock is rated ‘Overweight’, indicating a positive outlook from analysts, and the target price is set significantly higher than the current market price, implying potential upside for investors. The report of a quarterly EPS that exceeded expectations supports this optimistic view. The increase in EPS expectations can lead to increased investor confidence, likely resulting in upward pressure on the stock price as market participants adjust their valuations based on this new information. Risks include the possibility that the predicted earnings improvements do not materialize as expected, which could lead to volatility or corrections in the stock price.Market Beat+ 2